Compare BioNano Genomics Inc (BNGO) vs Flagstar Bank NA (FLG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Flagstar Bank NA — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Flagstar Bank NA trades at $14.2 (market cap $5.89B). The key difference: Flagstar Bank NA is far larger — about 431.2× BioNano Genomics Inc's market cap, and Flagstar Bank NA pays a 0.28% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | FLG | |
|---|---|---|
Market Cap | $13.66M | $5.89B |
Sector | Health | Financials |
52-Week High | $4.92 | $15.36 |
52-Week Low | $1.06 | $10.72 |
Enterprise Value | $16.26M | — |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
FLG trades at $14.21, up 1.43% today, with a bullish technical signal from moving averages. The stock shows a low P/B of 0.77 but a high P/E of 473, reflecting recent profitability after a 2025 net loss. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and declared dividends, signaling financial strength. Analyst consensus is a Buy with a $16.85 price target, indicating potential upside from current levels.
The outlook is cautiously optimistic, supported by analyst bullishness and strategic initiatives like technology transformation. Key risks include earnings volatility, competitive pressures in banking, and macroeconomic sensitivity. The stock presents a value opportunity based on price-to-book, but sustained earnings growth is crucial for justifying the elevated P/E ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →
